ArticleMolecular therapy. Nucleic acids2019
Artificial Circular RNA Sponges Targeting MicroRNAs as a Novel Tool in Molecular Biology.
Article in Molecular therapy. Nucleic acids, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- The "cutting edge" of non-canonical RNA splicing.Frontiers in molecular biosciences · 2026Review
- The multiplex crosstalk between non-coding RNAs, programmed cell death and related mechanisms: a dynamic duo in hematological malignancies.Cancer cell international · 2025Review
- CircRNA-based AntimiR therapy: A novel approach to hypertension treatment.Non-coding RNA research · 2025Review
- Circular RNAs in cancer.MedComm · 2025Review
- Interplay of microRNAs and circRNAs in Epithelial Ovarian Cancer.Non-coding RNA · 2024Review
- Advanced approaches of the use of circRNAs as a replacement for cancer therapy.Non-coding RNA research · 2024Review
- Optimal delivery of RNA interference by viral vectors for cancer therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Review
- Exosomal circular RNAs: New player in breast cancer progression and therapeutic targets.Frontiers in genetics · 2023Review
- Review
- Circular RNA PVT1 promotes progression of thyroid cancer by competitively binding miR-384.Experimental and therapeutic medicine · 2022Article
- Circular RNA circSFMBT2 downregulation by HBx promotes hepatocellular carcinoma metastasis via the miR-665/TIMP3 axis.Molecular therapy. Nucleic acids · 2022Article
- CircMYC promotes proliferation, migration, invasion and inhibits apoptosis of small cell lung cancer by targeting miR-145/ Matrix Metallopeptidase 2 axis.Bioengineered · 2022Article
- Engineering synthetic RNA devices for cell control.Nature reviews. Genetics · 2022Review
- Specific expression and functions of circular RNAs.Cell death and differentiation · 2022Review
- Circular RNA circHIPK3 Activates Macrophage NLRP3 Inflammasome and TLR4 Pathway in Gouty Arthritis via Sponging miR-561 and miR-192.Inflammation · 2021Article
- Circular RNAs: Expression, localization, and therapeutic potentials.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Review
- The Roles of CircRNAs in Bladder Cancer: Biomarkers, Tumorigenesis Drivers, and Therapeutic Targets.Frontiers in cell and developmental biology · 2021Review
- CircITCH: A Circular RNA With Eminent Roles in the Carcinogenesis.Frontiers in oncology · 2021Review
- CircRNA expression profiling and bioinformatics analysis indicate the potential biological role and clinical significance of circRNA in influenza A virus-induced lung injury.Journal of biosciences · 2021Article
- Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy.Molecular cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.